US FDA Pushes Back GSK’s Momelotinib Decision
Ruling Now Expected By 16 September
GSK remains confident of approval despite the delay, with hopes of blockbuster sales for its myelofibrosis candidate.
GSK remains confident of approval despite the delay, with hopes of blockbuster sales for its myelofibrosis candidate.